GlyProVac ApS: Financial statements 2021
CVR: 39724758
Source: annual report 2021, Danish Business Authority
01/07/2020 – 30/06/2021
GlyProVac ApS (CVR 39724758) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 993,453 and a net result of DKK -487,049 compared with DKK -698,589 the year before. That is a decrease of 5.5% compared with the year before. Equity in the 2021 report amounted to DKK 2,435,086. The solvency ratio was 25.6%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 993,453
- Profit/Loss
- DKK -487,049
- Equity
- DKK 2,435,086
- Total Assets
- DKK 9,529,102
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 993 t. | -487 t. | 2.4 mio. | 3 |
| 2020 | - | 1.1 mio. | -699 t. | 672 t. | 4 |
| 2019 | - | 145 t. | -918 t. | 1.4 mio. | 2 |
Official annual report
Find more companies like GlyProVac ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of August 29, 2021, Willem Adriaan de Jongh has joined the board of directors of GlyProVac ApS.
About GlyProVac ApS
GlyProVac ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Anders Boysen and Ann Zahle Andersen. The board consists of Ann Zahle Andersen (chair), Allan Rosetzsky, Kirsten Winther and Willem Adriaan de Jongh. The company's owners include Bente Kristiansen, Rossi Finans ApS and I/S Rødeledsvej. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -2,128,863 and a net result of DKK -5,168,999 compared with DKK -3,014,952 the year before. Equity in the 2025 report amounted to DKK -831,720.